INMB
INmune Bio Inc
NASDAQ: INMB · HEALTHCARE · BIOTECHNOLOGY
$1.33
-5.00% today
Updated 2026-04-29
Market cap
$39.08M
P/E ratio
—
P/S ratio
781.61x
EPS (TTM)
$-1.86
Dividend yield
—
52W range
$1 – $8
Volume
0.4M
INmune Bio Inc (INMB) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-61,738.00%
ROE
-165.20%
ROA
-53.70%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2015 | $0.00 | $-48868.00 | — | — | — |
| 2016 | $0.00 | $-277000.00 | — | — | — |
| 2017 | $0.00 | $-831000.00 | — | — | — |
| 2018 | $0.00 | $-12.44M | — | — | — |
| 2019 | $77.69M | $-7.68M | 100.00% | -9.98% | -9.88% |
| 2020 | $10916.00 | $-12.10M | 100.00% | -112,016.09% | -110,838.76% |
| 2021 | $181000.00 | $-30.34M | 100.00% | -16,106.63% | -16,762.43% |
| 2022 | $374000.00 | $-28.65M | 100.00% | -6,938.77% | -7,659.63% |
| 2023 | $155000.00 | $-30.01M | 100.00% | -19,187.74% | -19,360.00% |
| 2024 | $14000.00 | $-42.08M | 100.00% | -304,535.71% | -300,585.71% |
| 2025 | $50000.00 | $-45.93M | 100.00% | -61,738.00% | -91,866.00% |